Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Boehringer Ingelheim Stories

2014-03-05 12:26:22

Boehringer Ingelheim and Lilly are committed to working with the FDA RIDGEFIELD, Conn. and INDIANAPOLIS, March 5, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (Lilly; NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the New Drug Application (NDA) of the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin. The complete response letter...

2014-03-01 12:20:30

For U.S. Media Only RIDGEFIELD, Conn., March 1, 2014 /PRNewswire/ -- Boehringer Ingelheim today presented data from Phase 3 studies of tiotropium delivered via the Respimat(®) inhaler in mild, moderate and severe asthma patients at the 2014 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting in San Diego. Tiotropium is being studied to determine its efficacy and safety in treating asthma patients and is not currently approved for this indication. The first results...

2014-02-27 23:38:29

Bloomberg reported on February 26 that, according to unsealed court filings, Boehringer didn’t share with the FDA an analysis showing a higher death rate from Pradaxa bleeding. In light of this news, AttorneyOne, a recognized authority on law, informs that they are now providing advice, including how to get in contact with legal counsel, to people potentially affected by Pradaxa side effects. San Diego, CA (PRWEB) February 27, 2014 AttorneyOne.com, a recognized authority on law, updated...

2014-02-24 23:03:02

The attorneys at Bernstein Liebhard LLP are evaluating potential Pradaxa lawsuit claims from individuals who may have experienced serious episodes of internal bleeding caused by the anti-coagulant. New York, NY (PRWEB) February 24, 2014 Thousands of recently-filed Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/) are alleging that certain researchers and medical institutions may have concealed vital safety data about the blood-thinner in clinical trials that led to its U.S. approval,...

2014-02-20 08:31:52

- Milestone achieved for BI's initiation of Phase 1 study in beta-secretase (BACE) inhibitor program FORT WASHINGTON, Pa., Feb. 20, 2014 /PRNewswire/ -- Vitae Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and advancing novel, small molecule, best-in-class compounds, announced today that it has earned a $14 million milestone payment from Boehringer Ingelheim (BI) for BI's initiation of a Phase 1 clinical trial in the companies' beta-secretase...

2014-02-19 23:27:36

As Reuters reported on February 13, Boehringer faces more than 2,000 US lawsuits claiming that Pradaxa caused severe and fatal bleeding. In light of this news, AttorneyOne, a recognized authority on law, informs that they are now providing advice, including how to get in contact with legal counsel, to people potentially affected by Pradaxa side effects. San Diego, CA (PRWEB) February 19, 2014 AttorneyOne.com, a recognized authority on law, updated the website recently and now, can...

2014-02-18 12:30:55

DURHAM, N.C., Feb. 18, 2014 /PRNewswire-iReach/ -- Health Decisions, Inc., the full-service clinical research organization of choice for forward-looking biopharma and medical device companies, today announced the appointment of Patrick Phillips, D Phil, as Vice President, Clinical Affairs. (Photo: http://photos.prnewswire.com/prnh/20140218/MN66379) "We are delighted to add a clinical affairs executive with outstanding capabilities, deep global experience and expertise in the...

2014-02-15 23:00:34

The Firm is evaluating Pradaxa lawsuits on behalf of individuals who suffered cerebral hemorrhage, gastrointestinal bleeding, and other serious bleeding events, allegedly due to Pradaxa. New York, New York (PRWEB) February 15, 2014 Boehringer Ingelheim has acknowledged being named a defendant in more than 2,000 Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/) pending in U.S. courts that allege the company failed to warn patients about the potential for serious and uncontrollable...

2014-02-12 23:31:05

Roger C. Denton, Plaintiffs' Co-Lead Counsel in the Pradaxa® MDL, provides update for the Pradaxa Multidistrict Litigation (MDL 2385), particularly that numerous internal company documents have been unsealed and made publicly available. St. Louis, MO (PRWEB) February 12, 2014 On February 7, 2014, The New York Times reported that numerous documents have been made public in the Pradaxa® Multidistrict Litigation entitled In re: Pradaxa® (Dabigatran Etexilate) Products...

2014-02-08 23:01:19

The Firm is evaluating Pradaxa lawsuits on behalf of individual who allegedly suffered serous episodes of Pradaxa bleeding. New York, New York (PRWEB) February 08, 2014 As Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/) continue to move forward, Bernstein Liebhard LLP notes that documents recently unsealed in the U.S. District Court, Southern District of Illinois, have shed new light on Boehringer Ingelheim’s marketing of the blood thinning drug. According to a report from The New...